Our Blog

03 Jun

Starpharma signs second oncology agreement with AstraZeneca

By Finance News

03 Jun 2019 – Starpharma (ASX:SPL) has today announced a Development and Option Agreement with AstraZeneca to progress the development (of a Dendrimer Enhanced Product (DEP) version )of an undisclosed AstraZeneca major marketed oncology medicine.


Source: Finance News Network

Share this post

Related Posts

11 Jan

Tech jumps as dip buyers arrest rout on late recovery: ASX to fall

11 Jan 2022 - Dip buyers arrested the tumble in tech shares for a... read more

22 Jan

Biden unveils federal pandemic response: Aus shares to open lower

22 Jan 2021 - The Australian share market looks set to open lower following... read more

11 May

Z Energy (ASX:ZEL) reports $88 million loss

11 May 2020 - Z Energy (ASX:ZEL) reported a net loss after tax of... read more

15 Jan

Gold bulls, energy investors take profits: Aus shares close 0.12% higher

15 Jan 2018 - Market Wrap Report: Gold and lithium companies shine but profit... read more

09 Feb

Business confidence rises in January: ASX tracking 0.4% lower at noon

09 Feb 2021 - The local market dropped at the open, the S&P/ASX 200... read more

16 Dec

Beach (ASX:BPT) provides Beharra Springs Deep update

16 Dec 2019 - Beach Energy Limited (ASX:BPT) has completed flow testing at the... read more

01 Jun

Fortescue reaches new record on the back of iron ore price surge, Aussie dollar pops: Aus shares finish 1.1% higher

01 Jun 2020 - The local sharemarket started the new month with a 1.1... read more

19 Feb

Seven Group Holdings (ASX:SVW) 1HFY20 profit, earnings and revenue higher

19 Feb 2020 - Diversified investment group, Seven Group holdings (ASX:SVW) has reported underlying... read more

18 Sep

International Cobalt Resources (ASX:ICR) to list on ASX

18 Sep 2018 - International Cobalt Resources Limited (ASX:ICR) Executive Director, Benjamin Cooper discusses... read more

13 May

CBA’s remediation costs weigh on profit

13 May 2019 - The Commonwealth Bank's (ASX:CBA) third quarter net profit has fallen... read more